Unknown

Dataset Information

0

If At First You Don't Succeed, Trikafta Again.


ABSTRACT: Adverse reactions, including severe cutaneous reactions, to cystic fibrosis transmembrane conductance regulator (CFTR) modulators have been described in the literature. Herein we present a drug eruption in response to elexacaftor/tezcaftor/ivacaftor (brand name, Trikafta) in a 7-year-old male with cystic fibrosis, followed by desensitization and successful continuation. A review of the literature outlining similar cases is provided. Attempting to mitigate and manage drug reactions to CFTR modulators is essential because they represent vital and irreplaceable therapies for individuals with cystic fibrosis (CF).

SUBMITTER: Loyd I 

PROVIDER: S-EPMC9268110 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature

altmetric image

Publications

If At First You Don't Succeed, Trikafta Again.

Loyd India I   Papac Nicole N   Hirshburg Jason J   Levin Jarad J   Dannelley Jennifer J   Dorris Janislynn J   Stratton Jason J   Mehdi Nighat N  

The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG 20220706 5


Adverse reactions, including severe cutaneous reactions, to cystic fibrosis transmembrane conductance regulator (CFTR) modulators have been described in the literature. Herein we present a drug eruption in response to elexacaftor/tezcaftor/ivacaftor (brand name, Trikafta) in a 7-year-old male with cystic fibrosis, followed by desensitization and successful continuation. A review of the literature outlining similar cases is provided. Attempting to mitigate and manage drug reactions to CFTR modula  ...[more]

Similar Datasets

| S-EPMC11529135 | biostudies-literature
| S-EPMC7163297 | biostudies-literature
| S-EPMC8819522 | biostudies-literature
| S-EPMC9703991 | biostudies-literature
| S-EPMC10232816 | biostudies-literature
| S-EPMC7702681 | biostudies-literature
| PRJEB45769 | ENA
| S-EPMC9912939 | biostudies-literature
| S-EPMC6534505 | biostudies-literature